Covidien Launches Oral Transmucosal Fentanyl Citrate Product
Links shared publicly online about this topic.
- 1,337total visits
Covidien Launches Oral Transmucosal Fentanyl Citrate Product
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to dis
View full resource at medicalnewstoday.com
Tags: Pain, Cancer Pain Medication, Healthcare, Duragesic, Actiq
Most Recently Shared on March 5, 2010 at 9:08 pm By:
Covidien Launches Oral Transmucosal Fentanyl Citrate Product http://mnt.to/3ywF #cancer
Also Shared By:
Covidien Receives FDA Approval For Oral Transmucosal Fentanyl Citrate Product
medicalnewstoday.com — “Covidien (NYSE: COV), a leading global provider of healthcare products, announced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbre” View full resource at medicalnewstoday.com
Most Recently Shared on November 2, 2009 at 3:37 pm By:
MNT Pain News Pain Management and Health News
Covidien Receives FDA Approval For Oral Transmucosal Fentanyl Citrate Product: Covidien (NYSE: COV), a leading .. http://bit.ly/2f6YVZ
Advertisement
MNT Pain News
@mnt_pain
Covidien Receives FDA Approval For Oral Transmucosal Fentanyl Citrate Product: Covidien (NYSE: COV), a leading .. http://bit.ly/2f6YVZ
1 year ago...